NP819404.RAdab MCq0vM0-t XcCIo pQ5WdULHzNJ-SL-R0eoh Q
has assertion: NP819404.RAdab MCq0vM0-t XcCIo pQ5WdULHzNJ-SL-R0eoh Q130 assertion
has provenance: NP819404.RAdab MCq0vM0-t XcCIo pQ5WdULHzNJ-SL-R0eoh Q130 provenance
has publication info: NP819404.RAdab MCq0vM0-t XcCIo pQ5WdULHzNJ-SL-R0eoh Q130 publicationInfo
type: Nanopublication
created: 2016-05-13T12:47:56+02:00
rights: http://opendatacommons.org/licenses/odbl/1.0/
rights holder: IBIGroup
subject: SIO_000983
used data: disgenetv3.0rdf
authored by: http://orcid.org/0000-0001-5999-6269
authored by: http://orcid.org/0000-0002-7534-7661
authored by: 0000-0002-9383-528X
authored by: http://orcid.org/0000-0003-0169-8159
authored by: http://orcid.org/0000-0003-1244-7654
created by: http://orcid.org/0000-0003-0169-8159
version: v4.0.0.0

NP819404.RAdab MCq0vM0-t XcCIo pQ5WdULHzNJ-SL-R0eoh Q130 assertion
type: Assertion
description: [We randomly assigned 560 HIV-1-infected pregnant women (CD4+ count, > or = 200 cells per cubic millimeter) to receive coformulated abacavir, zidovudine, and lamivudine (the nucleoside reverse-transcriptase inhibitor [NRTI] group) or lopinavir-ritonavir plus zidovudine-lamivudine (the protease-inhibitor group) from 26 to 34 weeks' gestation through planned weaning by 6 months post partum.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine.
evidence: DisGeNET evidence - LITERATURE
SIO_000772: http://identifiers.org/pubmed/20554983
was generated by: ECO_0000203

befree-2016
imported on: 2016-02-19

DisGeNET evidence - LITERATURE
type: ECO_0000212
comment: Gene-disease associations inferred from text-mining the literature.

disgenetv3.0rdf
version: v4.0.0